http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Jang, Soobin,Jang, Bo-Hyoung,Ko, Youme,Sasaki, Yui,Park, Jeong-Su,Hwang, Eui-Hyoung,Song, Yun-Kyung,Shin, Yong-Cheol,Ko, Seong-Gyu Hindawi Publishing Corporation 2016 Evidence-based Complementary and Alternative Medic Vol.2016 No.-
<P><I>Objective</I>. The aim of this systematic review is to evaluate the efficacy and safety of herbal medicines in the management of metabolic syndrome.<I> Materials and Methods</I>. On December 9, 2015, we searched PubMed, EMBASE, Cochrane Library, SCOPUS, AMED, CNKI, KoreaMed, KMBASE, OASIS, and J-STAGE with no restriction on language or published year. We selected randomized controlled trials that involved patients with metabolic syndrome being treated with herbal medicines as intervention. The main keywords were “Chinese herbal medicines”, “metabolic syndrome”, and “randomized controlled trials”. Herbal substances which were not based on East Asian medical theory, combination therapy with western medicines, and concurrent diseases other than metabolic syndrome were excluded. The risk of bias was assessed by Cochrane's “Risk of Bias” tool. The protocol or review was registered in PROSPERO (an international prospective register of systematic reviews) (CRD42014006842).<I> Results</I>. From 1,098 articles, 12 RCTs were included in this review: five trials studied herbal medicines versus a placebo or no treatment, and seven trials studied herbal medicines versus western medicines. Herbal medicines were effective on decreasing waist circumference, blood glucose, blood lipids, and blood pressure.<I> Conclusion</I>. This study suggests the possibility that herbal medicines can be complementary and alternative medicines for metabolic syndrome.</P>
( Hyoung Su Kim ),( Hyung Joon Yim ),( Myoung Kuk Jang ),( Sang Joon Suh ),( Yeon Seok Seo ),( Sun Young Yim ),( Soon Ho Um ),( Ji Hoon Kim ),( Bo Hyun Kim ),( Sang Jong Park ),( Sae Hwan Lee ),( Sang 대한간학회 2013 춘·추계 학술대회 (KASL) Vol.2013 No.1
Background/Aims: Little is known about efficacy of rescue therapy for ETV resistance. This study was aimed to evaluate the efficacy of adefovir (ADV)-based combination regimens for CHB patients with ETV resistance. Methods: A total of 48 CHB patients with ETV genotypic resistance and without ADV exposure, who received rescue therapy with ADV-based combination regimens for at least 12 months, were enrolled and analysed in this multicenter retrospective study. Initial virologic response at 3 months (IVR-3) and virologic response (VR) were defined as HBV DNA <3.3 log10 IU/mL after 3 months of treatment and HBV DNA was undetectable by PCR assay during the treatment. Results: Thirty five (72.9%) patients were men, and their median age was 46.5 (22-74) years. Twelve patients (25.0%) had liver cirrhosis and 45 patients (93.8%) were HBeAg. All patients but one had a history of exposure to prior nucleoside analogue. Mean HBV DNA levels were 5.50 (±1.24) log10 IU/mL, and the median duration of ETV therapy was 24 (13-58) months. ADV+lamivudine (LAM) (n=28) and ADV+ETV (n=20) were used as rescue therapies. VR was observed in 17 patients (35.4%) and HBeAg seroconversion occurred in 6 patients (13.3%). Seven patients (14.6%) were primary non responders. ADV+ETV was superior to ADV+LAM in HBV DNA reduction (HBV DNA levels at baseline, 3, 6 and 12 months; 5.24, 2.65, 2.40 and 2.18 vs. 5.69, 3.86, 3.55 and 3.20 log10 IU/mL, P=0.006). In multivariate analysis, baseline HBV DNA levels (<5.2 log10 IU/mL) and IVR-3 were independent predictive factors for VR. Patients with low baseline HBV DNA and IVR-3 achieved VR in 81.3% (13/16). Conclusions: Although ADV combination therapy showed limited efficacy for CHB patients with ETV resistance, ADV+ETV combination could be considered in patients who have low HBV DNA titer and be continued in the presence of IVR-3.
Jang, Soobin,Kim, Kyeong Han,Sun, Seung-Ho,Go, Ho-Yeon,Lee, Eun-Kyung,Jang, Bo-Hyoung,Shin, Yong-Cheol,Ko, Seong-Gyu Hindawi 2017 Evidence-based Complementary and Alternative Medic Vol.2017 No.-
<P><I>Background.</I> This survey aimed to investigate the characteristics of users and nonusers of herbal medicine and the adverse events experienced due to herbal medicines in South Korea.<I> Methods.</I> The questionnaire consisted of safety, using experience, using type, usage and nonusage reason, purchase location, and adverse events of herbal medicine. The survey was administered by online.<I> Results.</I> Of the total 1,134 respondents, 726 (64.0%) considered herbal medicine safe, and 693 (61.1%) answered that they have taken herbal medicines within the past year. Most common place to purchase them was “TKM hospital or clinic” (63.6%), and most participants (72.2%) took a decoction from a TKM institution. The biggest reason for taking them was for “health improvement” (57.3%), and the reasons for not using them was “medication not necessary” (63.7%). Among those who took herbal medicines, 46 experienced adverse events, and the most frequently reported symptoms were digestive disorders (52.2%). Of the 46 participants who experienced adverse events, 20 (43.5%) were treated by TKM doctors.<I> Conclusions.</I> This study suggests that regulation of herbal medicines is needed in order to resolve problems related to the safety of herbal medicines. </P>
Jang, Hee Yeon,Zhang, Ke,Chon, Bo Hyun,Choi, Hyoung Jin Elsevier 2015 Journal of industrial and engineering chemistry Vol.21 No.-
<P><B>Abstract</B></P> <P>This study compared the potential applications of xanthan gum and hydrolyzed polyacrylamide (HPAM) as polymer-flooding agents for heavy oil recovery applications under a range of salinity conditions. Rheological measurements were carried out to examine the change in shear viscosity when the polymer was applied under a range of reservoir conditions. The results showed that the shear viscosity of the xanthan gum solution was less sensitive to increasing temperatures and salinity than that of the HPAM solution. Accordingly, a xanthan gum injection is more effective than HPAM under higher salinity reservoir conditions.</P>
Chronic Periodontitis and Risk of Lung Cancer: A Nationwide Longitudinal Cohort Study
( Bo-guen Kim ),( Dong Won Park ),( Hyun Lee ),( Sun-kyung Lee ),( Sun Young Paik ),( Seo-hyoung Yun ),( Chang-joo Park ),( Yoomi Yeo ),( Tai Sun Park ),( Ji-yong Moon ),( Tae-hyung Kim ),( Jang Won S 대한결핵 및 호흡기학회 2023 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.136 No.0
( Bo Kyung Yang ),( Byung Ju Do ),( Eun Jung Kim ),( Ji Un Lee ),( Mi Hee Kim ),( Jin Gu Kang ),( Hyoung Su Kim ),( Kyung Ho Kim ),( Myoung Kuk Jang ),( Jin Heon Lee ),( Hak Yang Kim ),( Woon Geon Shi The Editorial Office of Gut and Liver 2014 Gut and Liver Vol.8 No.1
Background/Aims: As the incidence rate of and mortality from pseudomembranous colitis (PMC) are increasing worldwide, it is important to study the simple predictive risk factors for PMC among patients with hospital-acquired diarrhea (HAD). This study focused on identifying the clinical risk factors that can easily predict PMC. Methods: The presumed HAD patients were prospectively recruited at the Hallym University Kangdong Sacred Heart Hospital. Results: Age of 70 and older (adjusted odds ratio [OR], 1.76, 95% confidence interval [CI], 1.12 to 0.75), use of proton pump inhibitors (adjusted OR, 4.07, 95% CI, 2.512 to 6.57), use of cephalosporins (adjusted OR, 2.99, 95% CI, 1.82 to 4.94), and underlying cancer (adjusted OR, 1.72, 95% CI, 1.04 to 2.82) were independent risk factors for PMC in the multivariate logistic regression analysis. The prevalence of PMC was very low in the patients with HAD who exhibited no risk factors. Conclusions: The risk factors for PMC in patients with HAD included cephalosporin use, proton pump inhibitor use, old age, and cancer. Considering the strongly negative predictive values of these risk factors, endoscopic evaluation can be delayed in patients with HAD without risk of developing PMC. (Gut Liver 2014,8:41-48)
임상연구 : 후두경을 이용한 이중관 기관지 튜브 삽관 시 심혈관계 반응을 억제하는 Remifentanil의 적정 용량
신형용 ( Hyoung Yong Shin ),서보병 ( Bo Byoung Seo ),이용철 ( Yong Cheol Lee ),김진모 ( Jin Mo Kim ),김애라 ( Ae Ra Kim ),장영호 ( Young Ho Jang ),배정인 ( Jung In Bae ),홍지희 ( Ji Hee Hong ) 대한마취과학회 2007 Korean Journal of Anesthesiology Vol.53 No.1
Background: The purpose of the present study was to determine the optimal dose of bolus remifentanil to attenuate hemodynamic changes to laryngoscopic double-lumen endobronchial intubation. Methods: A total of 80 ASA I or II patients requiring double-lumen endobronchial intubation were randomly assigned to receive normal saline (NS) or one of the three different doses (0.5μg/kg (group R0.5), 1.0μg/kg (group R1.0) or 2.0μg/kg (group R2.0)) of remifentanil. Study drugs for each group were administered over 30 seconds after induction of anesthesia with thiopental sodium and rocuronium. Laryngoscopic endobronchial intubation was carried out 90 seconds after the administration of study drug. Arterial blood pressure and heart rate were recorded at preanesthetic baseline, preintubation, postintubation, and every one minute during the initial 5 minute period after intubation. Results: Mean arterial pressure at postintubation period increased significantly compared to baseline value in group NS, R0.5, and R1.0, but there were no significant changes in group R2.0. Heart rate showed significant increase in comparison to baseline value at every postintubation period in group NS, R0.5, R1.0, with no significant changes in group R2.0. Conclusions: We suggest that 2.0μg/kg of remifentanil attenuate the hemodynamic changes to double-lumen endobronchial intubation without adverse effect. (Korean J Anesthesiol 2007; 53: 48~53)